Urothelial carcinoma is the most common bladder cancer, with stage 1 indicating early-stage disease confined to the bladder lining. Diagnosis involves urinalysis, cystoscopy, TURBT, and imaging to ...

More than 250,000 people undergo a transurethral procedure each year in the U.S., and up to 10% of those people will experience a postoperative infection. But researchers have discovered an indicator ...

UGN-102 showed high complete response rates in both ENVISION and ATLAS trials for low-grade, intermediate-risk NMIBC. Dysuria was the most common side effect of UGN-102, with other side effects ...

The benefit-risk profile was favorable, supporting UGN-102 mitomycin gel as a nonsurgical alternative to TURBT in patients with recurrent low-grade, intermediate-risk non-muscle invasive bladder ...

(StatePoint) When John noticed blood in his urine, he consulted his doctor and was quickly referred to a urologist. (John is a composite character, based on the experiences of real-life patients.) ...

PORTLAND, OR - It's just one step. Flushing the bladder with a common chemotherapy drug after a cancerous tumor is surgically removed reduces the chances of that cancer returning. Canadian and ...

PRINCETON, N.J--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, ...